| TSR-022 (Anti-TIM-3 Antibody) and TSR-042 (Anti-PD-1 Antibody) in Patients With Liver Cancer (NCT03680508) | University of Hawaii | 2019-12-19 |
| Hepatic Arterial Infusion of Oxaliplatin and Fluorouracil Treatment of Advanced Primary Liver Cancer After TACE (NCT02557503) | Zhu Xu | 2015-01-01 |
| Chinese Herbal Formulation PHY906 and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer (NCT01666756) | City of Hope Medical Center | 2014-06-11 |
| PET-CT in Determining the Radioembolization Dose Delivered to Patients With Liver Metastasis, Primary Liver Cancer, or Biliary Cancer (NCT02088775) | Fox Chase Cancer Center | 2014-02-01 |
| 3-Tesla MRI Response to TACE in HCC (Liver Cancer) (NCT02057874) | Vanderbilt-Ingram Cancer Center | 2014-02-01 |
| Pilot Study to Assess Lung Shunting of Yttrium-90 Microspheres Using PET/CT (NCT02119065) | University of Cincinnati | 2014-01-30 |
| CPI-613 in Treating Patients With Advanced or Metastatic Bile Duct Cancer That Cannot Be Removed By Surgery (NCT01766219) | Wake Forest University Health Sciences | 2013-05-01 |
| Sorafenib Tosylate With or Without Stereotactic Body Radiation Therapy in Treating Patients With Liver Cancer (NCT01730937) | Radiation Therapy Oncology Group | 2013-04-01 |
| Selumetinib and Akt Inhibitor MK-2206 in Treating Patients With Refractory or Advanced Gallbladder or Bile Duct Cancer That Cannot Be Removed By Surgery (NCT01859182) | National Cancer Institute (NCI) | 2013-01-01 |
| Veliparib, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Advanced Biliary, Pancreatic, Urothelial, or Non-Small Cell Lung Cancer (NCT01282333) | National Cancer Institute (NCI) | 2011-01-01 |
| Radiolabeled Glass Beads in Treating Patients With Liver Cancer That Cannot be Removed by Surgery (NCT02072356) | Ohio State University Comprehensive Cancer Center | 2010-10-11 |
| Cediranib Maleate and Combination Chemotherapy in Treating Patients With Advanced Biliary Cancers (NCT01229111) | National Cancer Institute (NCI) | 2010-10-01 |
| AZD2171 in Treating Patients With Locally Advanced Unresectable or Metastatic Liver Cancer (NCT00427973) | National Cancer Institute (NCI) | 2009-05-01 |
| Sorafenib Tosylate in Treating Patients With Liver Cancer Who Have Undergone a Liver Transplant (NCT00844168) | University of Washington | 2009-01-01 |
| Sunitinib Malate and Capecitabine in Treating Patients With Unresectable or Metastatic Liver Cancer (NCT00787787) | University of Washington | 2008-09-01 |
| IMC-A12 in Treating Patients With Advanced Liver Cancer (NCT00639509) | National Cancer Institute (NCI) | 2008-03-01 |
| Selumetinib in Treating Patients With Locally Advanced or Metastatic Liver Cancer (NCT00604721) | National Cancer Institute (NCI) | 2007-11-01 |
| Dasatinib in Treating Patients With Advanced Liver Cancer That Cannot Be Removed by Surgery (NCT00459108) | National Cancer Institute (NCI) | 2007-04-01 |
| Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer (NCT00397384) | National Cancer Institute (NCI) | 2007-01-01 |
| Bevacizumab and Erlotinib in Treating Patients With Advanced Liver Cancer (NCT00365391) | National Cancer Institute (NCI) | 2006-08-01 |
| Belinostat in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery (NCT00321594) | National Cancer Institute (NCI) | 2006-05-01 |
| Cediranib Maleate in Treating Patients With Locally Advanced or Metastatic Liver Cancer (NCT00238394) | National Cancer Institute (NCI) | 2005-12-01 |
| Lapatinib Ditosylate in Treating Patients With Unresectable Liver or Biliary Tract Cancer (NCT00107536) | National Cancer Institute (NCI) | 2005-10-01 |
| Lapatinib in Treating Patients With Locally Advanced or Metastatic Biliary Tract or Liver Cancer That Cannot Be Removed By Surgery (NCT00101036) | National Cancer Institute (NCI) | 2004-11-01 |
| EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer (NCT00087191) | National Cancer Institute (NCI) | 2004-05-01 |
| Doxorubicin and Bortezomib in Treating Patients With Liver Cancer (NCT00083226) | National Cancer Institute (NCI) | 2004-03-01 |
| Gefitinib in Treating Patients With Advanced Unresectable Hepatocellular Carcinoma (Liver Cancer) (NCT00071994) | National Cancer Institute (NCI) | 2004-02-01 |
| Bortezomib in Treating Patients With Unresectable Locally Advanced or Metastatic Adenocarcinoma of the Bile Duct or Gallbladder (NCT00085410) | National Cancer Institute (NCI) | 2004-01-01 |
| Oxaliplatin in Treating Patients With Liver Cancer (NCT00052364) | National Cancer Institute (NCI) | 2002-09-01 |
| Erlotinib in Treating Patients With Liver Cancer That Cannot be Surgically Removed (NCT00047333) | National Cancer Institute (NCI) | 2002-08-01 |
| Erlotinib in Treating Patients With Unresectable Liver Cancer and Liver Dysfunction (NCT00047346) | National Cancer Institute (NCI) | 2002-08-01 |
| Erlotinib in Treating Patients With Unresectable Liver, Bile Duct, or Gallbladder Cancer (NCT00033462) | National Cancer Institute (NCI) | 2002-03-01 |
| 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007) (NCT00031681) | National Cancer Institute (NCI) | 2001-12-01 |
| Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction (NCT00030498) | National Cancer Institute (NCI) | 2001-12-01 |
| Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer (NCT00028496) | National Cancer Institute (NCI) | 2001-11-01 |
| BMS-247550 in Treating Patients With Liver or Gallbladder Cancer (NCT00023946) | National Cancer Institute (NCI) | 2001-08-01 |
| Thalidomide and Chemoembolization With Doxorubicin in Treating Patients With Liver Cancer That Cannot be Removed by Surgery (NCT00006016) | National Cancer Institute (NCI) | 2000-05-01 |
| Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu (NCT00004074) | National Cancer Institute (NCI) | 1999-08-01 |